Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Combination epigenetic and immunotherapy overcomes resistance to monoclonal antibodies in hematologic malignancies: A new therapeutic approach.

Epner EM, Saroya BS, Hasanali ZS, Loughran TP Jr.

Exp Hematol. 2016 Mar;44(3):157-60. doi: 10.1016/j.exphem.2015.12.011. Epub 2016 Jan 21. Review.

PMID:
26802532
2.

Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia.

Hasanali ZS, Saroya BS, Stuart A, Shimko S, Evans J, Vinod Shah M, Sharma K, Leshchenko VV, Parekh S, Loughran TP Jr, Epner EM.

Sci Transl Med. 2015 Jun 24;7(293):293ra102. doi: 10.1126/scitranslmed.aaa5079.

3.

Apoptotic circulating tumor cells (CTCs) in the peripheral blood of metastatic colorectal cancer patients are associated with liver metastasis but not CTCs.

Allen JE, Saroya BS, Kunkel M, Dicker DT, Das A, Peters KL, Joudeh J, Zhu J, El-Deiry WS.

Oncotarget. 2014 Apr 15;5(7):1753-60.

4.

Contradictory KRAS mutation test results in a patient with metastatic colon cancer: a clinical dilemma in the era of personalized medicine.

Lamparella NE, Saroya BS, Yang Z, Sarwani NE, El-Deiry WS.

Cancer Biol Ther. 2013 Aug;14(8):699-702. doi: 10.4161/cbt.25095. Epub 2013 Jun 12.

5.

Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer.

Al-Marrawi MY, Saroya BS, Brennan MC, Yang Z, Dykes TM, El-Deiry WS.

Cancer Biol Ther. 2013 Aug;14(8):703-10. doi: 10.4161/cbt.25191. Epub 2013 Jun 13.

6.

Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers.

Desai MD, Saroya BS, Lockhart AC.

Expert Opin Investig Drugs. 2013 Mar;22(3):341-56. doi: 10.1517/13543784.2013.761972. Epub 2013 Jan 15. Review.

PMID:
23316969

Supplemental Content

Loading ...
Support Center